[go: up one dir, main page]

NO20073566L - Oksyindol-derivater som agonister for 5HT4-reseptor - Google Patents

Oksyindol-derivater som agonister for 5HT4-reseptor

Info

Publication number
NO20073566L
NO20073566L NO20073566A NO20073566A NO20073566L NO 20073566 L NO20073566 L NO 20073566L NO 20073566 A NO20073566 A NO 20073566A NO 20073566 A NO20073566 A NO 20073566A NO 20073566 L NO20073566 L NO 20073566L
Authority
NO
Norway
Prior art keywords
esophageal
disease
compounds
dyspepsia
pharmaceutically acceptable
Prior art date
Application number
NO20073566A
Other languages
English (en)
Norwegian (no)
Inventor
Hiroki Sone
Chikara Uchida
Kiyoshi Kawamura
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20073566L publication Critical patent/NO20073566L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20073566A 2005-02-22 2007-07-10 Oksyindol-derivater som agonister for 5HT4-reseptor NO20073566L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65527605P 2005-02-22 2005-02-22
PCT/IB2006/000519 WO2006090279A1 (fr) 2005-02-22 2006-02-10 Derives d'oxyindole utilises comme agonistes du recepteur 5ht4

Publications (1)

Publication Number Publication Date
NO20073566L true NO20073566L (no) 2007-08-08

Family

ID=36579484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073566A NO20073566L (no) 2005-02-22 2007-07-10 Oksyindol-derivater som agonister for 5HT4-reseptor

Country Status (32)

Country Link
US (2) US7589109B2 (fr)
EP (1) EP1856110B1 (fr)
JP (1) JP4130220B1 (fr)
KR (1) KR100908547B1 (fr)
CN (1) CN101522668B (fr)
AP (1) AP2007004067A0 (fr)
AR (1) AR053548A1 (fr)
AT (1) ATE513827T1 (fr)
AU (1) AU2006217534B8 (fr)
BR (1) BRPI0607456A2 (fr)
CA (1) CA2598536C (fr)
DK (1) DK1856110T3 (fr)
DO (1) DOP2006000046A (fr)
EA (1) EA012615B1 (fr)
ES (1) ES2366375T3 (fr)
GE (1) GEP20094727B (fr)
GT (1) GT200600083A (fr)
HK (1) HK1135966A1 (fr)
HN (1) HN2006007884A (fr)
IL (1) IL184505A0 (fr)
MA (1) MA29260B1 (fr)
MX (1) MX2007010139A (fr)
NL (1) NL1031218C2 (fr)
NO (1) NO20073566L (fr)
NZ (1) NZ556627A (fr)
PE (1) PE20061096A1 (fr)
TN (1) TNSN07319A1 (fr)
TW (1) TW200640915A (fr)
UA (1) UA86301C2 (fr)
UY (1) UY29389A1 (fr)
WO (1) WO2006090279A1 (fr)
ZA (1) ZA200706420B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
EP1856110B1 (fr) * 2005-02-22 2011-06-22 Pfizer Inc. Derives d'oxyindole utilises comme agonistes du recepteur 5ht4
CA2611639A1 (fr) * 2005-06-29 2007-01-04 Merck & Co., Inc. 4-fluoro-piperidines antagonistes du canal calcium de type t
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP5205971B2 (ja) * 2006-01-27 2013-06-05 宇部興産株式会社 テトラヒドロピラン化合物の製造方法
WO2008021422A2 (fr) * 2006-08-17 2008-02-21 Wyeth Procédé de préparation de dérivés d'indolin-2-one servant de modulateurs du récepteur de la progestérone
WO2009112874A1 (fr) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Composition à libération modifiée comprenant de la doxofylline
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
ES2547415T3 (es) * 2009-02-27 2015-10-06 Raqualia Pharma Inc Derivados de oxiindol con actividad agonista del receptor de motilina
JP5649645B2 (ja) * 2009-05-07 2015-01-07 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンアナログの固形製剤
ES2578628T3 (es) 2009-09-14 2016-07-28 Suven Life Sciences Limited Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4
EP2533780B1 (fr) * 2010-02-12 2017-08-23 AskAt Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
SI2758394T1 (sl) * 2011-09-19 2015-05-29 Suven Life Sciences Limited Heteroaril spojine kot 5-ht4 receptor ligandi
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
EP3392244A1 (fr) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
EA201691594A1 (ru) 2014-02-13 2017-02-28 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
EP3626720A1 (fr) 2015-04-03 2020-03-25 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
DK3334709T3 (da) * 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
EP3416666B1 (fr) * 2016-02-16 2021-10-27 Strongbridge Dublin Limited Compostions pharmaceutiques de veldoréotide hydrosoluble à faible solubilité dans les conditions physiologiques et méthodes de production
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
CN114105863B (zh) * 2021-12-07 2023-11-28 江苏汉拓光学材料有限公司 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5552408A (en) * 1987-09-23 1996-09-03 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
AU1161292A (en) 1991-01-09 1992-08-17 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9121170D0 (en) 1991-10-05 1991-11-20 Smithkline Beecham Plc Pharmaceuticals
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) * 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5280028A (en) * 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5521193A (en) * 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
FR2694292B1 (fr) 1992-07-29 1994-10-21 Esteve Labor Dr Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament.
NZ257545A (en) * 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
TW251287B (fr) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9312348D0 (en) 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
US5534521A (en) * 1993-06-23 1996-07-09 G. D. Searle & Co. Benzimidazole compounds
CA2134192A1 (fr) 1993-11-12 1995-05-13 Michael L. Denney Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9414139D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
DE4440675A1 (de) 1994-11-14 1996-05-15 Basf Ag Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
AU9309898A (en) * 1997-09-09 1999-03-29 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
WO2000026197A1 (fr) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Nouveaux inhibiteurs de l'enzyme impdh
AU784848B2 (en) 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
WO2002030886A2 (fr) 2000-10-12 2002-04-18 Matthews Barry R Inhibiteurs d'angiogenese heterocycliques
KR20030059835A (ko) 2000-12-07 2003-07-10 씨브이 쎄러퓨틱스, 인코포레이티드 관상동맥 질환 또는 동맥경화증에 대한 ａｂｃａ-1 상승화합물로서의 1,3,5-트리아진 및 피리미딘
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
JP4671123B2 (ja) 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
GEP20084527B (en) 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
MXPA06014486A (es) * 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1856110B1 (fr) * 2005-02-22 2011-06-22 Pfizer Inc. Derives d'oxyindole utilises comme agonistes du recepteur 5ht4

Also Published As

Publication number Publication date
US20100173925A1 (en) 2010-07-08
HK1135966A1 (en) 2010-06-18
CA2598536A1 (fr) 2006-08-31
AP2007004067A0 (en) 2007-08-31
GT200600083A (es) 2006-11-07
HN2006007884A (es) 2010-01-18
CA2598536C (fr) 2011-04-05
EP1856110B1 (fr) 2011-06-22
JP4130220B1 (ja) 2008-08-06
AU2006217534B2 (en) 2011-08-11
GEP20094727B (en) 2009-07-10
MA29260B1 (fr) 2008-02-01
NZ556627A (en) 2010-09-30
CN101522668A (zh) 2009-09-02
BRPI0607456A2 (pt) 2009-09-08
NL1031218A1 (nl) 2006-08-23
DOP2006000046A (es) 2006-08-31
ZA200706420B (en) 2009-04-29
AR053548A1 (es) 2007-05-09
KR20070098936A (ko) 2007-10-05
US20060194842A1 (en) 2006-08-31
PE20061096A1 (es) 2006-11-09
AU2006217534B8 (en) 2011-12-08
AU2006217534A1 (en) 2006-08-31
UA86301C2 (en) 2009-04-10
EP1856110A1 (fr) 2007-11-21
UY29389A1 (es) 2006-10-02
CN101522668B (zh) 2012-06-06
JP2008531543A (ja) 2008-08-14
IL184505A0 (en) 2007-10-31
MX2007010139A (es) 2007-09-27
TNSN07319A1 (fr) 2008-12-31
ATE513827T1 (de) 2011-07-15
WO2006090279A1 (fr) 2006-08-31
EA012615B1 (ru) 2009-10-30
NL1031218C2 (nl) 2007-01-23
TW200640915A (en) 2006-12-01
US7589109B2 (en) 2009-09-15
EA200701552A1 (ru) 2007-12-28
ES2366375T3 (es) 2011-10-19
DK1856110T3 (da) 2011-08-15
AU2006217534A8 (en) 2011-12-08
KR100908547B1 (ko) 2009-07-20

Similar Documents

Publication Publication Date Title
NO20073566L (no) Oksyindol-derivater som agonister for 5HT4-reseptor
NO20065160L (no) Derivater av benzimidazolon karboksylisk syre
DE602006010563D1 (de) Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
NO20061519L (no) Benzimiflazolonforbindelser som har 5HT4-reseptorantagonistisk aktivitet
UY29421A1 (es) Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones.
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
JP2009502770A5 (fr)
US20060183902A1 (en) Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
BRPI0510022A (pt) compostos de tienopiridinona e processos de tratamento
WO2006041985A3 (fr) Composes de thienopyridinone et methodes therapeutiques
NZ602612A (en) Novel benzamide derivatives
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
US9382208B1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2
US10538491B2 (en) 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CU20070183A7 (es) Derivados de oxindol
DOP2005000113A (es) Drivados de acido carboxilico de bencimidazolona
TH76314A (th) สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application